$CALC News

CalciMedica Announces Stephen Bardin To Resign As CFO Effective After Q3 2026 10-Q Filing

CalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock Offering

CalciMedica Regains Nasdaq Compliance

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

CalciMedica Announces One-for-Five Reverse Stock Split

CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28

Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss

CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis

CalciMedica Files Prospectus For Resale Of Up To 56,020,287 Shares

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial

CalciMedica Announces Private Placement Worth Up To ~$49M In Gross Proceeds

CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate